Two medicines, side by side
Indapamide vs metolazone
Indapamide and metolazone are both labeled for high blood pressure, heart failure and edema (fluid retention). Drugs@FDA records approvals of indapamide since 1983 and of metolazone since 1973. Pharmacies paid $0.109 per indapamide 1.25 mg tablet and $0.233 per metolazone 2.5 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like.
Check it at the source: the indapamide FDA label on DailyMed (effective October 1, 2022); the metolazone FDA label on DailyMed (effective December 11, 2025).
Highlights of the indapamide record
Indapamide (Lozol) · label of October 1, 2022
Used for
From the label: indicationsIndapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see PRECAUTIONS ). […]
On the market
- Earliest approval on file
- July 6, 1983
- Generic labelers
- 8 labelers
- Pharmacy cost
- $0.109 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the metolazone record
Metolazone (Zaroxolyn) · label of December 11, 2025
Used for
From the label: indicationsMetolazone tablets, USP, are indicated for the treatment of salt and water retention including: edema accompanying congestive heart failure; edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets, USP, are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. […]
On the market
- Earliest approval on file
- November 27, 1973
- Generic labelers
- 19 labelers
- Pharmacy cost
- $0.233 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Source: FDA drug labels via openFDA (Indapamide label of October 1, 2022, Metolazone label of December 11, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do indapamide and metolazone differ on the record?
Both are in FDA's class thiazide-like diuretics.
Generics: indapamide since 1995; metolazone since 2003 (Drugs@FDA).
| Indapamide | Metolazone | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure, Edema (fluid retention) | High blood pressure, Edema (fluid retention), Heart failure |
| Pharmacologic class | Thiazide-like Diuretic | Thiazide-like Diuretic |
| How it works (label) | n/a | n/a |
| Half-life (label) | The half-life of indapamide in whole blood is approximately 14 hours. | n/a |
| Earliest approval on file (Drugs@FDA) | July 6, 1983 | November 27, 1973 |
| First generic approved | July 27, 1995 | December 19, 2003 |
| Generic labelers (NDC) | 8 labelers | 19 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.109 per tablet (Indapamide 1.25 mg tablet) | $0.233 per tablet (Metolazone 2.5 mg tablet) |
| 12-month price change | +9% | +8% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 0 | 0 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 17,817 | 11,175 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to indapamide
- every medicine labeled for the same conditions